<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668158</url>
  </required_header>
  <id_info>
    <org_study_id>ZJHZXU2017</org_study_id>
    <nct_id>NCT03668158</nct_id>
  </id_info>
  <brief_title>Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma</brief_title>
  <official_title>Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish molecular subtyping of HCC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma is one of the most common malignant tumors in the world with high
      incidence and mortality. Liver transplantation is the most effective treatment for HCC and is
      in high demand in China. However, recurrence of HCC among liver transplantation recipients is
      still a great challenge and threat to the survival of recipients. So it is of great
      significance to establish molecular subtyping of HCC and achieve precise selection of
      recipients. Based on large scales of samples, the investigator's study aims to establish
      multi-omics characteristic profiles of liver transplantation for HCC in integration of
      apparent biological characteristics, clinical management and prognostic information by
      utilizing genomics, transcriptomics and proteomics, etc. This study will contribute to the
      therapy-oriented molecular subtyping of HCC.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>recurrent HCC</arm_group_label>
    <description>recurrent HCC after LT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-recurrent HCC</arm_group_label>
    <description>non- recurrent HCC after LT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalization patient
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Liver transplantation due to HCC within Hangzhou criteria

        Exclusion Criteria:

        Liver transplantation due to HCC beyond Hangzhou criteria Liver transplantation due to
        other disease except HCC Multiple organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Xiao Xu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

